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INTRODUCTION
1. Herpesviruses: general features
1.1 Classification of herpesviruses
More than 100 herpesviruses have been discovered, all of them are double-stranded DNA 
viruses that can establish latent infections in their  respective hosts. Eight herpesviruses 
infect humans.
Figure 1. Phylogenetic tree of Herpesviridae.
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The  Herpesviridae  family includes  three  subfamilies:  the  Alpha-,  Beta-,  and 
Gammaherpesvirinae 1  (Figure  1). The  Alphaherpesvirinae are defined by wide cellular 
host range, shorter viral reproductive cycle, rapid growth in culture, high cytotoxic effects, 
and the ability to establish latency in sensory ganglia. Human α-herpesviruses are herpes 
simplex viruses 1 and 2 (HSV1 and HSV2) and varicella zoster virus (VZV).                   
The Betaherpesvirinae have a more restricted host range with a longer reproductive viral 
cycle and slower growth in culture. Infected cells show cytomegalia (enlargement of the 
infected cells).  Latency is established in secretory glands, lymphoreticular cells, and in 
different  tissues,  such  as  the  kidneys  and  others.  In  humans,  these  are  human 
cytomegalovirus (HCMV) and  roseoloviruses (causing  the  disease  roseola  infantum in 
children)  including  human  herpesviruses  6A and  6B (HHV6A and  6B)  and  human 
herpesvirus 7 (HHV7).
The  Gammaherpesvirinae in  vitro  replication  occurs  in  lymphoblastoid  cells,  but  lytic 
infections may occur in epithelial and fibroblasts for some viral species in this subfamily.  
Γ-herpesviruses are specific for either B or T cells with latent virus found in lymphoid 
tissues. The γ-herpesviruses subfamily contains two genera that include both the  γ-1 or 
Lymphocryptovirus (LCV) and the  γ-2 or Rhadinovirus (RDV) virus genera.  Only two 
human  γ-herpesviruses  are  known to date,  human herpesvirus  4,  or  Epstein-Barr  virus 
(EBV), and  human herpesvirus 8,  referred to as HHV8 or Kaposi's sarcoma-associated 
herpesvirus  (KSHV).  EBV  is  the  only  Lymphocryptovirus  and  HHV8  is  the  only 
Rhadinovirus discovered in humans. LCV are found only in primates whereas RDV can be 
found in both primates and subprimate mammals.
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Table 1. Human herpesviruses classification and characteristics.
1.2 Structure of herpesviruses
Herpesviruses have a central toroidal-shaped viral core containing a linear double stranded 
DNA. This DNA is embedded in a proteinaceous spindle 2. The capsid is icosadeltahedral 
(16  surfaces)  with  2-fold  symmetry  and  a  diameter  of  100-120  nm  that  is  partially 
dependent  upon  the  thickness  of  the  tegument.  The  capsid has  162  capsomeres.  The 
herpesvirus  tegument,  an  amorphous  proteinaceous  material  that  under  EM  lacks 
distinctive features, is found between the capsid and the envelope; it can have asymmetric 
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distribution. Thickness of the tegument is variable depending on the location in the cell and 
varies  among  different  herpesviruses  3.  The  herpesvirus  envelope contains  viral 
glycoprotein protrusions on the surface of the virus (Figure 2), and by EM it appears as a 
lipid trilaminar structure, derived from the cellular membranes.
Figure 2. Schematic representation of a herpesvirus virion (left) and a EM picture of the herpesvirus particle 
(right).
1.3 Herpesviruses genome
Herpesviruses genomes studied to date range in size from 130 to 235 kbp. Herpesviruses 
DNA is characterized by two unique components, unique long (UL) and unique small (US) 
regions, each flanked by identical inverted repeat sequences (TRL and IRL:  Terminal and 
Internal  repeats)  (Figure  3).  Herpesvirus  genome  also  contains  multiple  repeated 
sequences. All known herpesviruses have capsid packaging signals at their termini 4. The 
majority of herpes genes contain upstream promoter and regulatory sequences, an initiation 
site followed by a 5' nontranslated leader sequence, the open reading frame (ORF) itself, 
some 3' nontranslated sequences, and finally, a polyadenylation signal. Gene overlaps are 
common, whereby the promoter sequences of antisense strand (3') genes are located in the 
coding region of sense strand (5') genes; ORFs can be antisense to one another.
Proteins can be embedded within larger coding sequences and yet have different functions. 
Most genes are not spliced and therefore are without introns and sequences for noncoding 
RNAs are present.
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Herpesviruses code for genes that synthetize proteins involved in establishment of latency, 
production of DNA, and structural proteins for viral replication, nucleic acid packaging, 
viral entry, capsid envelopment, for blocking or modifying host immune defences, and for 
transition from latency to lytic growth. Although all herpesviruses establish latency, some 
(e.g.,  HSV) do not necessarily require latent protein expression to remain latent, unlike 
others (e.g., EBV and HHV6).
Figure 3. Genomic organization of human herpesviruses.
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1.4 Replication of herpesviruses
Herpesviruses can establish lytic or latent infections. The lytic stage can be divided in 6 
phases:
I.  Binding to the cell surface. Virus attachment and entry require sequential interactions 
between specific viral membrane glycoproteins and cellular receptors.   
II-III.  Fusion of the virion membrane with the host cell membrane; then the capsid and 
some tegument proteins are transported to the nucleus along cellular microtubules. Upon 
entry into the cytoplasm, the nucleocapsid is transported to the nuclear pores, where viral 
DNA  is released into the nucleus.   
IV.  Virus transcription,  replication and translation.  This is  a very complex process,  as 
expected  considering  the  large  size  of  viral  genome.  Viral  DNA  replicates  by 
circularization followed by production of concatemers and cleavage of unit-length genome 
during packaging (“rolling-circle” mechanism).
Herpesviruses transcription is temporally regulated, and can be divided into four steps:
   α or immediate early (IE) genes expression, requiring no prior viral protein synthesis 
and mRNAs are frequently detectable within 3 h after infection.. The proteins encoded in 
this stage are expressed first and are involved in transactivating transcription from other 
viral genes. Expression of IE gene products is essential for the activation of transcription 
from early gene promoters.
   β or  early  (E) genes expression, which is independent of viral DNA synthesis. The 
early  protein  transcribed  are  involved  in  DNA metabolism and  DNA replication.  The 
expression of  β genes is dependent on α gene expression.
   γ1 or partial late genes expression, which starts in concert with the beginning of viral 
DNA synthesis.
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   γ2 or  late (L) genes expression, which is totally dependent upon synthesis of viral 
DNA and  expression  of  structural  genes  encoding  for  capsid  proteins  and  envelope 
glycoproteins occurs.
Herpesviruses DNA is transcribed to RNA by cellular RNA polymerase I. The neo-formed 
viral mRNAs block cellular protein synthesis and activate the replication of viral DNA. 
Herpesviruses encode their own DNA-dependent DNA polymerase and other enzymes and 
proteins  necessary to  replication,  such as  ori-Lyt  (replication  start  for  the lytic  phase), 
major  DNA  binding  protein  (MDBP)  and  origin  DNA  binding  protein  (OBP). 
Herpesviruses can alter their environment by affecting host cell protein synthesis and host 
cell DNA replication, immortalizing the host cell, and altering the host's immune responses 
(e.g.,  blocking apoptosis,  cell  surface  MHC I  expression,  modulation  of  the  interferon 
pathway).
V. Assembly: capsids are assembled in the nucleus.
VI.  Viral exit. The viral particles bud through the inner lamella of the nuclear membrane 
which has been modified by the insertion of viral glycoproteins and leave the cell via the 
exocytosis pathway, or by budding from the cell membrane or by lysis.
The phases of a typical productive cycle are summarized in Figure 4.
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Figure 4. The cycle of productive HSV replication in a cell. The stages of HSV infection are: (1) Receptor  
binding and membrane fusion; (2) Release of the viral nucleocapsid and tegument into the cell cytoplasm and 
transport of the nucleocapsid to the nuclear pore; (3) Release of viral DNA into the nucleus; (4) Transcription 
and  translation  of  the  viral  immediate  early  (IE)  and  early  (E)  genes;  (5)  viral  DNA synthesis;  (6) 
Transcription and translation of the viral late (L) genes; (7) capsid assembly and DNA packaging; and (8) 
egress of progeny virions.
All herpesviruses can establish latent infections in their natural host. Such an infection is 
characterized  by periods  of  highly restricted  (or  no)  viral  gene  expression  in  the  cells 
harboring the latent genomes, interspersed with periods of virus replication and infectivity 
(reactivation).  The  different  type  of  herpesviruses  carry  out  latency  and  reactivation 
processes in generally similar ways, but details depend on the specific virus. Neurotropic 
herpesviruses  like  α-herpesvirinae  (i.e.  HSV) establish  a  latent  infection  by entering  a 
sensory nerve axon near the infection site. The virus particle  then migrates to the neuron 
nucleus in the nerve ganglion (Figure 5). If virus gene expression occurs normally, viral 
DNA replication and cell death will occur; however, in most infected neurons, the earliest 
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stages of gene expression appear to be blocked. Thus, these neurons are nonpermissive for 
replication.  This  results  from the  fact  that  one  or  several  cellular  transcription  factors 
required to express the immediate-early genes are absent or present in a modified form. 
The  viral  genome  of  herpesviruses  is  not  fully  shut  off  during  latent  infection;  one 
transcript termed the latency-associated transcripts (LAT) is expressed from a single latent 
phase active promoter.
Figura 5.  Stages of  HSV infection.  (A) HSV replicates initially in epithelial  cells  at  the genital  or oral  
mucosal surface. The virus enters innervating sensory neurons where it travels up the axon to the neuronal 
cell body. Once in the neuron, the virus establishes a latent infection that may last the lifetime of the host. (B) 
Upon the proper stimulus, the virus can reactivate, travel back down the axon, and establish another round of  
lytic replication.
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Since  viral  DNA is  in  the  neuronal  nucleus  and  fully  differentiated  neurons  do  not 
replicate,  the  DNA can remain  silent  for  long period  of  time.  Then,  when the  host  is 
stressed with certain agents the cellular transcriptional environment change and immediate-
early as well as other viral transcripts are expressed at detectable levels. This is sufficient 
for  the  replication  of  virus  in  at  least  a  few  neurons,  which  results  in  the  transitory 
appearance of a small amount of virus that travels down the axon and reinfects the area 
where the virus first infected, producing a new lytic infection in the target epithelial cells.
2.  Human herpesvirus 6
Human  herpesvirus  type  6  (HHV6)  was  first  isolated  in  1986  from  peripheral  blood 
lymphocytes (PBL) of patients with lymphoproliferative disorders 5. Initially the virus was 
named "Human B lymphotropic virus" (HBLV) because it seemed to manifest a tropism for 
B cells, but subsequent studies have shown that the preferential cellular target are T cells 6. 
The International Committee on Taxonomy of Viruses has finally named the virus HHV6 7. 
HHV6 is  a  members of  the  Betaherpesvirinae subfamily,  included in the  Roseolovirus 
genus along with HHV7. Members of this genus are characterized by elective tropism for T 
lymphocytes, the ability to grow with less efficiency also in other cell types, high rates of 
latent  infection  in  the  human  population,  and  by  association  with  childhood  febrile 
syndromes, which might be accompanied by rash.
Furthermore, HHV6 strain cluster in two variants (HHV6A and HHV6B), which differ on 
the basis of distinct genetic, immunological and biological characteristics  8, and for the 
associated diseases, as detailed in the “Disease association” chapter.
HHV6 is highly prevalent in the healthy population, establish latency in macrophages and 
T-lymphocytes,  is  frequently  shed  in  saliva  of  healthy  donors,  and  their  pathogenic 
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2.1 Virion
HHV6 virion, as for all herpesviruses, have four main structural elements: an electron-
dense  core,  a  capsid with icosahedral  symmetry,  a  tegument,  and an outer  envelope in 
which  virally  encoded  glycoproteins  and  integral  membrane  proteins  are  embedded  1 
(Figure 6).
Figure 6. A) Schematic representation of HHV6. B) Electron microscope photograph of HHV6 virions in 
infected  lymphoid cells. Bar is 100 nm.
The assembly process  leading to  mature  HHV6 particles  begins  in  the nucleus,  where 
nucleocapsids are assembled. HHV6 capsids have a diameter of 90 to 110 nm 10,11. After 
capsid  assembly,  the  tegument  is  acquired  while  still  in  the  nucleus  by  a  series  of 
envelopment and de-envelopment steps which have not been fully characterized 12,13. The 
tegument  may be  acquired  in  a  novel  structure,  the  tegusome,  which  is  a  membrane-
bounded spherical compartment, apparently of cytoplasmic origin, that is present in the 
nuclei  of  HHV6  infected  cells  13.  Fully  tegumented  capsids,  with  a  diameter  of 
approximately 165 nm, appear to be released into the cytoplasm via fusion of the tegusome 
with  the  nuclear  membrane  13,11.  HHV6  morphogenesis  has  the  unique  feature  of 
cytoplasmic  accumulation  of  fully  tegumented  capsids  with  a  prominent  and  well 
demarcated  tegument;  these  tegumented  cytoplasmic  capsids  appear  to  acquire  their 
15
                                                                                     
                                                                                          
                                                                                          Introduction
envelope by budding into cytoplasmic vesicles. Mature virions are approximately 200 nm 
in diameter 10,11 and are released by exocytosis 13,14.
2.2 Genome
HHV6  genome  is  composed  of  a  linear,  double-stranded  DNA molecule,  that  was 
completely sequenced in 1995 15. The genome is 160-162 kbp in size and is formed by a 
central  unique  region  (approximately 143 kbp)  bound at  both  ends  by terminal  direct 
repeats (each 8-9 kbp long) (Figure 7). The direct repeats contain genetic elements that are 
necessary for  viral  DNA packaging and replication  16 and  include  a  tandem repetitive 
sequence that is also present in human telomers 17. The genome of HHV6B is predicted to 
contain 119 open reading frames (ORFs), 9 of which are absent in HHV6A. ORFs encoded 
in the terminal direct repeats are identified with the prefix DR and those in the unique 
region are named U1-100, starting from the left end of the genome. Coding regions are 
located on both DNA strands,  and a few genes are spliced after transcription.  Overall, 
nucleotide  sequence  identity  between  HHV6A and  HHV6B  is  90%,  with  variability 
according to specific regions. Some DNA regions are conserved between variants for over 
95%, and other regions show higher divergence, with homology as low as 75% 18. Instead, 
variability within variants is very low, and viral strain belonging to the same variant differ 
by 1% or less across their genomes 19.
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Figure 7. Genomic organization of HHV6. The asterisk indicates the start of lytic genomic replication. Viral 
telomeric sequences are indicated by green bars T1 and T2. Open arrows represent protein coding regions.
Most of HHV6 genes are conserved and present in the genome of all herpesviruses, and 
can be organized in seven gene blocks (Figure 8), including genes U27 – U82.
The products of HHV6 genes U27, U41, U43, U74, U77, and U73 are involved in viral 
replication. The protein product of gene U27 encodes the DNA polymerase processivity 
factor,  binding  to  DNA  polymerase  and  thus  enhancing  the  rate  of  viral  genome 
transcription.
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Figure 8. Schematic representation of HHV6 and HHV7 genomes, showing the direct  repeats (DR), the 
position of the seven conserved herpesvirus gene blocks, of the β-herpesvirus specific genes, and of the two 
HHV6 specific genes (U83 and U94).
Gene  U41  encodes  a  single  stranded  DNA  binding  protein,  also  facilitating  DNA 
polymerase interaction with the viral genome. The protein products of genes U43, U74, 
and U77 produce a viral helicase-primase complex that facilitates replication of the viral 
genome. Additionally, the origin-binding protein produced by gene U73 is also involved in 
genomic DNA replication.
HHV6 attachment to host cells is facilitated by viral surface proteins gB and gH, encoded 
by viral genes U39 and U48, respectively 20.
One additional gene block includes 17 genes which are conserved only in β-herpesviruses, 
including genes U2 – U14.
There are also genes specific to Roseoloviruses, not present in the other β-herpesviruses, 
including U20-21, U23-24, U26, U85 and U100. Finally, two genes are unique to HHV6 
and present in both variants. One is U83, which encodes a chemokine with chemotactic 
activity  for  monocytic  cells,  and  is  expressed  in  two  forms.  The  spliced  variant  is 
expressed  as  an  early  protein,  before  DNA replication,  and  the  full  length  protein  is 
expressed only after DNA replication 21. The other gene unique to HHV6 is U94, encoding 
a homologue of the human adeno-associated virus type 2 (AAV-2) rep gene  22. The U94 
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gene product complements the replication of Rep-defective AAV-2 mutants, it localizes in 
the  nucleus  of  the  infected  cell  and  binds  to  the  human  TATA-binding  protein,  a 
transcription factor 23. It is transcribed as an IE gene and in latently infected lymphocytes 
24, suggesting that it likely contributes to the maintenance of latency 9.
2.3 DNA replication
The  elements  required  for  lytic  HHV6 DNA replication  are  the  origin  for  lytic-phase 
replication (oriLyt) and 7 viral gene products: the MDBP (major DNA binding protein), the 
DNA polymerase, a polymerase-associated protein, an origin binding protein (OBP), and a 
helicase-primase  complex.  An  interesting  feature  is  that  HHV6  encodes  a  sequence 
homolog of the HSV-1 OBP, which has been found only in α-herpesviruses 25, 26, 27, 28, 29. 
The HHV6 OBP, like other α-herpesvirus encoded OBP homologs, has greater amino acid 
sequence similarity to other herpesvirus OBPs in the N-terminal helicase region than in the 
C-terminal DNA binding region 27, 30.                                 
The  HHV6 oriLyt  (as  in  HSV-1,  VZV,  and  HCMV) is  located  upstream of  the  gene 
encoding the MDBP homolog 31, 32, 33. The HHV6 origin lies in a unique 1,400-bp region 
that has no protein-coding capacity and is located between the genes encoding the MDBP 
and the HCMV UL69/HSV-1 ICP27 homolog 34, 30, 35. These oriLyt sequences have been 
functionally  defined  by  using  transient-transfection  assays  with  plasmids  containing 
different portions of the HHV6 oriLyt 34: a region of approximately 400 bp was identified 
as  the  minimal  active  region.  The  HHV6  oriLyt  is  located  in  a  genomic  region  that 
includes two binding sites, OBP-1 and OBP-2, for the HHV6 OBP. The OBP sites are 
arranged  with  dyad  symmetry,  flank  an  AT-rich  spacer,  and  are  within  the  minimum 
essential origin region. This region is adjacent to a larger AT-rich imperfect direct repeat of 
about 195 bp that has been proposed to act as a DNA-unwinding element  34. Both OBP 
sites are required for DNA replication in transient-transfection assays 36 (Figure 9).
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Figure 9. Schematic diagram of human herpesvirus 6 (HHV6)  oryLit.
2.4 Internal repeated items
Several repeated items are located in the UL region of the HHV6 genome, namely: R0, R1, 
R2, R3. These elements are placed in correspondence with regions of the genome with a 
low percentage of identity between the two variants of the virus. R0 is present only in 
HHV6B and is located near the junction between DRL and UL and within the ORF putative 
B4.
R1 is  located  near the  3’  end of  ORF U86 and  determines,  once  translated,  the
production of a series of serine and arginine (SR) repeated in the carboxy terminal portion
U86 protein.
R2 is located in the region between U86 and U90. In the genome of HHV6A, R2 consists 
of repetitions of TG dinucleotide, in HHV6B are identified in the same region 2 distintict 
items repeats: R2A and R2B. R2A contains several TATA sequences; R2B is similar to R2 
of HHV6A, but is much shorter and contains multiple potential binding sites for the factor
HNF transcription-5 37,  suggesting a possible role of these sequences in the regulation of 
transcription 38.
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R3 is located upstream of the IE-A locus, which includes ORFs from U86 up to U91, and
contains regulatory elements that may play a role in the regulation of transcription of this 
locus.  The  region is  highly  variable among  the variants of  the virus  but
retains some sites in the consensus sequence of conserved regulatory elements 38.
2.5 HHV6 replicative cycle
The  infectious  cycle  of  HHV6  begin  with  the  interaction  between  specific  virus 
glycoproteins of the envelope (gB, gH, gL, gQ) and the specific receptor  on the cellular 
membrane, CD46. HHV6 enters in the cell through an endocytic pathway 40 (Figure 10). 
Unenveloped nucleocapsids are then released into the cytosol and migrate to the nucleus 
where the viral DNA is transcribed and replicated.
As already described for herpesviruses in general, during lytic infection, herpesvirus genes 
are  expressed  as  three  kinetic  classes  39.  The  α,  or  immediate-early  (IE),  genes  are 
transcribed with no requirement for de novo protein synthesis and α proteins regulate the 
expression of other genes. The second class of genes, the β or early (E) genes, are involved 
in DNA metabolism and DNA replication. The expression of β genes is dependent on α-
gene expression. The third class of genes is the γ, or late (L), genes; the products of these 
genes  are  usually involved in  virion  assembly and as  components  of  the mature  virus 
particle 14.
The  newly  produced  capsid  proteins  are  assembled  to  form  the  viral  core.  The 
nucleocapsid is than expelled from the nucleus in two forms: as a  mature-like particle, 
vehicled toward the cell surface within cytoplasmic vacuoles, or as a free cytosolic particle 
coated by a  seemingly amorphous tegument  structure,  which  subsequently buds into a 
cytoplasmic vacuole, possibly of Golgi origin, thereby acquiring the viral envelope. The 
maturation  cycle  culminates  with  the  final  expulsion  of  the  mature  particles  from the 
cellular membrane.
Like all herpesviruses, HHV6 can persist latently in the host following primary infection. 
Persistence may include both a true latent state, without production of infectious virus, and 
chronic replication with continuous or intermittent production of infectious progeny.
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Both forms of persistence develop in the same individual, with chronic infection taking 
place  mostly  in  salivary  glands  41,42,  while  true  latent  infection,  with  episodes  of 
reactivation, occurs mainly in macrophages and CD4+ T cells 43,44,45,46.
   
Figure 10. Schematic representation of HHV6 replication cycle.
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PCR  studies  have  shown  that  HHV6  DNA sequences  can  also  be  detected  in  many 
different tissues from asymptomatic  healthy individuals,  including urinary tract,  genital 
mucosa, fibroblasts and epithelium, thyroid, pancreas, liver 47,48.
However, there is no evidence that the virus can reactivate from these sites. It has been 
reported that latently infected cells contain four species of latency-associated transcripts, 
originating from the IE1/IE2 genic regions, with a transcription pattern similar to that of 
human  cytomegalovirus  49.  Another  transcript  expressed  during  latent  infection,  in  the 
absence of transcripts from lytic genes, is U94 50.
2.6 Cell tropism
HHV6  is  characterized  by  a  broad  tropism  for  different  human  cell  types,  and  this 
observation is in accordance with the fact that the cellular receptor is the CD46 molecule 
51,  a  ubiquitous  type-1  glycoprotein  member  of  a  family of  regulators  of  complement 
activation.  However,  only  few  cell  lines  expressing  CD46  support  efficient  viral 
replication, suggesting that in addition to the presence of receptor,  there is the need of 
specific requirements still unidentified.
HHV6A and HHV6B variants differ in the respective ability with which they can replicate 
in specific transformed T-lymphocyte cell lines. In addition, also CD8 T lymphocytes, γδ T 
lymphocytes and natural killer (NK) cells support HHV6 replication 52,53,54.
HHV6 can also infect macrophages, dendritic cells, fibroblasts, epithelial cells and bone-
marrow progenitors  55,56,57,58,59. Laboratory strains have been adapted to grow in specific 
human T cell lines, including Jurkat, J-Jhan, HSB2 for HHV6A, Molt-3, MT4 and SupT1 
for HHV6B  60 , but the efficiency of viral replication is 1-2 fold lower than in primary 
cells. Both variants are neurotropic and can infect neural cells, including astrocytes and 
oligodendrocytes, but HHV6B supports only abortive infection, while HHV6A establishes 
a productive infection that subsequently develops into latency 61,62.
HHV6 can also infect endothelial cells, both in vitro and in vivo 63, establishing a low level 
productive infection 64. Both HHV6A and HHV6B can infect fibroblasts, but only HHV6A 
produces  low amounts  of  infectious  progeny  65.  Therefore,  the  experimental  evidence 
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shows  that  HHV6A and  HHV6B have  differences  in  their  cell tropism,  and  possibly 
HHV6A is more virulent, but the reasons for this difference are still unknown 9.
2.7 Effects on cells
HHV6 infection causes significant alterations on the host cell metabolism. As is common 
with herpesviruses, infection induces shut off of host cell  DNA synthesis  66,  stimulates 
protein  synthesis  67,  and  causes  T  lymphocytes  to  develop  a  cytopathic  effect  with 
characteristic ballooning (Figure 11), refractile and syncithial cells. Viral infection induces 
differential secretion of a wide array of cytokines and chemokines, including interferon-α, 
interleukin 1β, RANTES, tumor necrosis factor and many others  64,68,69,70, depending on 
the virus and the cell type involved. HHV6 infection upregulates CD4 in T lymphocytes 
and induces its expression in CD4-negative cells 9.
Figure 11. Cytopathic effects of HHV6 (ballooning): CD4+ T lymphocytes non infected (on the left) and 
   HHV6-infected (on the right). Pictures was obtained  by phase contrast microscopy after 7 days p.i., 100X.
2.8 Epidemiology
HHV6 is ubiquitous and has a worldwide distribution. Seroprevalence is very high in the 
adult population, and specific IgG antibodies to HHV6 are detected in more than 90% of 
adults. Primary infection occurs during early childhood. The peak for HHV6 infection is 
observed  at  6-9  months  of  age  71.  There  are  no  convenient  serological  assays  to 
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discriminate between HHV6 variants,  however the available evidences suggest that the 
majority of clinical infections in immunocompetent patients are caused by HHV6B. In fact, 
the  viral  sequences  detected by  PCR in  latently  infected  peripheral  blood  cells  from 
healthy individuals belong almost invariably to HHV6B 72,73  , supporting the notion that 
HHV6A is less prevalent or that it establishes latency in different body districts. HHV6A is 
detected more often in immunocompromised than in immunocompetent hosts, and appears 
to be potentially more neurotropic  74. The mode of  transmission is unclear, but HHV6 
replicates  in  epithelial  cells  and  is  present  in  saliva,  suggesting  that  oral  secretions 
contribute  to  transmission,  especially  for  HHV6B  75,76,59.  Congenital  infections  occur 
approximately  in  1% of  births  and  are  asymptomatic  77.  Sequence  analysis  of  HHV6 
isolated from mother/infant pairs suggests that mother-to-infant transmission can occur 78, 
whereas there is no convincing evidence of sexual spread 9.
2.9 Disease association
HHV6 can be considered an opportunistic pathogen which persists asymptomatically in 
immunocompetent  individuals  but  can  cause  severe  pathologies  in  the  context  of 
immunosuppression.
Primary HHV6B infection in children causes  exanthem subitum (ES) (roseola infantum, 
sixth disease) with high fever and the development of a rash after resolution of fever  79. 
However,  only  a  subset  (17%)  of  children  with  acute  infection  develop  ES,  and  the 
majority suffer from undifferentiated short febrile illness, without appearance of rash 80,81. 
Although usually mild, ES may be accompanied by convulsions 82,80. Rare complications 
include hepatitis, arthritis, encephalopathy and haemophagocytosis syndrome 80,83. Primary 
infection in older age groups is rare and results in an undifferentiated febrile illness or in an 
heterophile-negative  infectious  mononucleosis  84,85.  Skin  rash,  hepatitis  and  atypical 
lymphocytosis may occur. HHV6A primary infection is not associated to ES and is likely 
mostly asymptomatic.
HHV6 related diseases in adults are mostly the results of reactivation, which might be 
clinically significant especially in the immunocompromised host. HHV6 can reactivate in 
immunocompetent  individuals  during pregnancy or periods  of critical  illness,  requiring 
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admission  to  intensive-care  units  86,87.  Many  reports  describe  other  possible  disease 
associations involving HHV6 reactivation 88. In particular, the central nervous system is a 
potential target for HHV6 pathogenesis. In fact, HHV6 DNA is often detected  in autoptic 
brain tissue from healthy individuals  89,90, indicating that the virus is able to invade and 
persist asymptomatically in the CNS. The pathogenic potential of HHV6 in the CNS is 
witnessed by several clinical reports 91.
HHV6  has  been  associated  with  neurological  complications  in  children  with  primary 
infection  92,93, encephalitis both in immunocompetent and immunocompromised patients 
94,95,  demyelinating  encephalomyelitis  96,97 and  chronic  myelopathy  98.  HHV6  DNA 
sequences are often detected in patients with temporal lobe epilepsy and the high levels of 
viral sequences suggest a potential etiological association  99,100,101. Some reports suggest 
that HHV6A may have higher neurotropism than HHV6B 102,103,104. For example, it was 
shown that HHV6A has a considerably higher prevalence in cerebrospinal fluid than in 
peripheral blood mononuclear cells or in saliva of children  105. The difficulty with these 
studies is that HHV6 infection is ubiquitous, it shows a wide tissue tropism, and therefore 
the  detection  of  viral  footprints  in  a  pathological  condition  is  not  univocal  proof  of 
etiology.  Viral  presence  might  be  due  to  latent  virus,  and  viral  reactivation  may be  a 
consequence, rather than the cause of disease. A further complication is the fact that there 
is not yet any biological explanation of how HHV6 variants might differentially contribute 
to the pathogenesis. The proposed association of HHV6 with multiple sclerosis (MS) is a 
paradigmatic example  of  how  difficult  it  is  to  substantiate,  or  to  disprove,  HHV6 
etiological association. In 1995, Challoner  106 proposed that HHV6 might be associated 
with MS. One of the original observations was the presence of HHV6 DNA sequences and 
antigens in the nuclei of oligodendrocytes from patients with MS adjacent to plaques of 
demyelination but not in control samples. The original report raised considerable interest, 
and subsequently, several studies were performed. However, after more years, the role of 
HHV6 in MS is still controversial.
There  is  substantial  evidence  that  HHV6  can  be  a  significant  pathogen  in 
immunocompromised hosts. HHV6 infection or reactivation in AIDS patients was reported 
to  cause  severe  disease,  such  as  fatal  pneumonitis,  encephalitis,  retinitis  and  HHV6 
dissemination to many organs 107. HHV6 is also an important pathogen in organ transplant 
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recipients  108,109,110.  HHV6 infection  or  reactivation  occurs  in  nearly  50% of  all  bone 
marrow  and  in  20-30%  of  solid-organ  transplant  recipients,  2-3  weeks  following  the 
procedure 108,111. Prospective studies employing DNA detection by PCR or viral culture in 
sequential blood samples post-transplantation provide the strongest evidence for HHV-6 
infection. The majority of HHV6 infections post-transplantation are due to reactivation of 
HHV6B,  and  the  peak  incidence  of  infection  is  2-4  weeks  post  transplantation  112,110. 
However, cases of primary infection due to transmission of the virus in donor tissue have 
been described, and superinfection with a donor strain distinct from the strain latent in the 
recipient may occur 113. Viral infection and/or reactivation may result in clinical symptoms, 
including  fever  (sometimes  associated  with  leukopenia),  skin  rash,  pneumonia,  bone 
marrow suppression,  encephalitis,  and transplant  failure  114,115,116,112,117.  Idiopathic  bone 
marrow suppression is more common in bone marrow transplant or stem-cell transplant 
recipients,  but  can  also  occur  following  solid  organ  transplantation  118,116,119.  Potential 
causes of marrow suppression include indirect effects mediated by cytokines and HHV6 
soluble products or direct infection of bone-marrow progenitors  120,121,122. In spite of the 
available evidence that HHV6 can be a serious pathogen responsible for complications in 
transplant recipients, definite proof is still  under debate, mainly because the underlying 
pathophysiologic mechanisms have not  yet  been elucidated.  Considerable attention has 
been focused on possible associations of HHV6 and the pathogenesis of AIDS because 
HHV6 replicates  in  CD4+ T cells,  the  primary  HIV-1  target,  but  studies  of  serologic 
responses to HHV6 in HIV-infected persons have yielded widely varying results 52.
Moreover,  a  possible  role  has  been  postulated  for  HHV6  in  a  variety  of  neoplastic 
disorders, but as yet there has been no conclusive demonstration that either HHV6A or 
HHV6B  is  involved  in  any  causative  way  with  any  malignancy.  Nevertheless,  the 
accumulated data suggest that at least for some neoplasms, there is more than a chance 
association with the virus.
Finally, HHV6 infection was also associated with the development of autoimmune diseases 
include  chronic  fatigue  syndrome,  graft  versus  host  disease,  encephalitis,  pneumonitis, 
graft failure. HHV6 has also been tentatively associated to several chronic autoimmune 
inflammatory  processes,  including  Sjogren  syndrome,  multiple  sclerosis,  rheumatoid 
arthritis and systemic lupus erythematosus-SLE. Recent case reports suggest that HHV6 
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infection might be related to the onset of autoimmune pathologies such as nonbacterial 
purpura  fulminans  and  severe  autoimmune  acquired  protein  S  deficiency,  autoimmune 
connective tissue diseases, severe autoimmune hepatitis.  
.
3. Infections and autoimmunity: the multifaceted relationship
The autoimmune diseases are a  diverse group of conditions characterized by abnormal 
immune reactivity in association with autoreactive B and T cell responses. There are more 
than 80 different autoimmune diseases 123 that affect hundreds of millions of people around 
the  world.  These  systemic  or  organ-specific  conditions  are  the  third  leading  cause  of 
morbidity and mortality in the industrial world after cancer and heart disease 124. Multiple 
factors are thought to contribute to the development of immune response to self, including 
differences in genotypes, hormonal milieu, and environmental factors 125,126.
The role of environmental factors is clearly apparent when considering the low disease 
concordance rate between monozygotic twins for major autoimmune diseases.
Of all environmental factors with a potential to trigger autoimmunity, the most important 
seems to be viruses, bacteria, and other infectious pathogens (Figure 12).
Figure 12. Diagram of factor interplay in autoimmune diseases.
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The pivotal role of infection in the induction of these disorders has been supported by 
several evidences, such as disease seasonal onset, disease occurrence after some infections, 
and the isolation of viral genomic DNA/RNA from affected tissues of patients once the 
disease  gets  started  127,128.  Infections  and  autoimmune  diseases  have  multifaceted  and 
multidirectional relationships 129.
The human immune system is highly complex, having evolved to fight a broad spectrum of 
pathogens. The host response to infections encompasses a huge number of immunological 
mechanisms  that  can  eventually  lead  to  autoimmunity.  Although  the  development  of 
autoimmune  phenomena  linked  to  infections  is  a  common  finding,  the  onset  of 
autoimmune diseases is a rare event, arising from a combination of genetic susceptibility 
and  environmental  factors  127,129,132,133.  There  are  several  mechanisms  through  which 
pathogens can initiate or perpetuate autoimmunity (Figure 13).
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Figure 13.  Host response and autoimmunity:  mechanisms that  can eventually lead to autoimmunity in a 
susceptible individual.
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Some of them are antigen-specific, including molecular mimicry, expression of modified, 
cryptic,  or  new antigenic determinants,  and superantigens.  Others are  non specific  and 
collectively  known  as  “bystander  activation.”  They  include  enhanced  processing  and 
presentation  of  self-antigens,  immune  cell  activation,  cytokine  release,  and  cell 
apoptosis/necrosis 134.
Molecular mimicry
In  molecular  mimicry,  pathogens  bear  elements  that  are  similar  enough in  amino acid 
sequence or structure to self-antigen. Immune response can eventually turn toward the self-
peptide as a result of cross-reactivity, leading to the activation of naıve, autoreactive T cells 
specific to the corresponding self-molecule 135,130.
Protein changes, cryptic antigens
Following tissue injury, cell death, oxidative stress, free radical production, and reparative 
changes, as happens in several infections, proteins that are usually recognized as self can 
became non self and induce an autoimmune response 134. This occurs as a consequence of 
protein  changes  as  a  result  of  altered  expression,  post-translational  modifications, 
denaturation, misfolding, or mutations 136. In addition, the inflammatory environment can 
induce differential processing of released self-epitopes by APCs. Proteins that are normally 
sequestered and shielded from immune recognition can be exposed to the immune system 
and become immunogenic. Therefore, cryptic antigens become accessible to self-reacting T 
lymphocytes  that  had  escaped  central  and  peripheral  tolerance,  as  they  had  not  been 
presented appropriately to induce tolerance.
Superantigens
Superantigens are proteins produced by a variety of microorganisms, especially bacteria or 
mycoplasmae,  or  virus-infected  cells  that  can  bind  TCR,  irrespective  of  its  antigenic 
specificity,  resulting in the activation of a large number of T lymphocytes of different 
antigenic specificity, thus behaving as a potent immune-stimulating molecule 134.
Bystander activation
It  is  a nonspecific mechanisms which is  defined as the activation of T cells  through a 
mechanism that is independent of specific TCR stimulation. Bystander activation can lead 
to enhanced processing and presentation of self-antigens, which induces the expansion or 
spreading of immune response toward different self-antigens. This last process, known as 
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epitope  spreading,  has  been  widely  involved  in  the  pathogenesis  of  many  systemic 
autoimmune diseases as well as in determining the different expression of such diseases 
137.
4. Autoimmune thyroid diseases
Autoimmune thyroid diseases (AITDs), are caused by an immune response to self thyroid 
antigens. Hashimoto's thyroiditis (HT), also known as chronic lymphocytic thyroiditis, is 
an autoimmune disease in which the thyroid gland is gradually destroyed by a variety of 
cell-  and  antibody-mediated  immune  processes.  It  was  first  described  by  Hashimoto 
Hakaru  in  Germany in  1912.  HT is  a  relatively common disease,  affecting  5-15% of 
women and 1-5% of men 138,139.
The development of the autoimmune failure of the thyroid is a multistep process, requiring 
several  genetic  and environmental  abnormalities to  converge  before  full-blown disease 
develops.  At  the  onset  of  disease,  major  histocompatibility  complex  (MHC)  class  II-
positive  antigen-presenting  cells  (APC),  particularly  dendritic  cells,  and  different 
subclasses of macrophages, accumulate in the thyroid 158,159. APC present thyroid-specific 
auto-antigens to the naïve T cells, leading to activation and clonal expansion of the latter. 
Thus,  the  initial  stage  of  the  disease  is  followed  by  a  clonal  expansion  phase  and 
maturation of autoreactive T and B lymphocytes in the draining lymph nodes.
The  mechanisms,  whereby  autoreactive  T  cells  escape  deletion  and  become  activated 
remain uncertain. There is evidence that the thyroid cell itself, by "aberrantly" expressing 
MHC  molecules,  can  play  the  role  of  "non-professional  "  APC  and  present  disease-
initiating antigen directly to the T cells 160,161.
A central phase of HT is characterized by the recognition of presented auto-antigens by the 
lymphocytes, followed by an apparent uncontrolled production of autoreactive CD4+ T 
cells, CD8+ cytotoxic T cells and immunoglobulin G (IgG) autoantibodies. Initially, the 
production of self-reactive cells and autoantibodies occurs in the draining lymph nodes. 
Later, the lymphoid tissue often develops directly in the thyroid gland itself. This tissue is 
generally very well organized, with cords of anti-Thyroglobulin (Tg)-antibody- producing 
plasma cells in the periphery.
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In a final, destructive step of Hashimoto's thyroiditis,  the autoreactive T cells diffusely 
accumulate in large numbers and infiltrate thyroid parenchyma, leading to destruction of 
thyrocytes (Figure 15).
Figure 15. Schematic model of cells death in Hashimoto’s  thyroiditis.
Two classes of autoantibodies are particularly relevant in the diagnosis of HT: anti-Tg Ab 
and anti-thyroperossidase (TPO) Ab.
Tg, the main protein synthesized in the thyroid, serves both in the synthesis and in the 
storage of thyroid hormones. Human Tg molecules contain at least four thyroid hormone 
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synthesis sites from the iodinated tyrosine residues. The hormone synthesis sites and the 
iodine content of Tg play an important role in its autoantigenicity  162. Tg is one of the 
major autoantigens in thyroid autoimmunity.
TPO is  another  significant  autoantigen in  the thyroid  of  patients  affected by HT. This 
enzyme catalyses the oxidation of iodine to an iodinating species that forms iodotyrosines 
in a Tg molecule and subsequently iodotyronines 163.
Autoimmune  responses  against  specific  antigens  are  primary  determinants  in  thyroid 
autoimmunity.  This process progressively destroy the thyroid cell  ultimately inducing a 
gradual reduction in thyrocyte numbers, leading to hypothyroidism 164,165.
The  disease  is  associated  with  several  genetic  and  environmental  factors,  and  the 
involvement of infectious agents, including viral infections, has been repeatedly suggested 
140,141. Several viruses have been incriminated, including influenza, coxackie, adenovirus, 
echovirus  and  mumps.  Herpesvirus  infection  has  occasionally  been  detected  in  AITD 
142,143, although there are no conclusive data. It has been shown that HCMV infection of 
thyrocytes  induces  HLA-DR  expression  on  thyroid  follicular  cells,  which  can  act  as 
antigen presenting cells 145. There are only scant data on the possible association between 
HHV6  infection  and  HT,  although  the  virus  has  been  implicated  in  the  onset  and/or 
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MATERIAL AND METHODS
1. Clinical samples
All  clinical  specimens  were  obtained  from  patients  referred to  the  Section  of 
Endocrinology of the University of Ferrara. Thyroid lesions were defined on the basis of 
ultrasound examination, and fine needle aspiration biopsy (FNAB) followed by cytological 
and laboratory tests.
A total of 62 patients were enrolled in the study after signing informed consent. None of 
them  had  other  concomitant  diseases  or  was  taking  drugs  possibly  affecting  thyroid 
function. Serum TSH, free T4, thyroperoxidase antibodies (TPO Ab; normal value < 35 
IU/ml) and thyroglobulin antibodies (Tg Ab; normal value < 115 IU/ml) were measured in 
all  patients  by using an  immuno-electrochemiluminescence  technique  (Modular  E 170, 
Roche Diagnostics GmbH). All patients underwent ultrasound (US) guided thyroid fine 
needle aspiration. Thyroid aspirates were used for both cytology and molecular analysis. 
The 34 HT patients showed TPO Ab > 35 IU/ml, ranging from 146 to 8229 IU/ml (mean 
value = 1312 IU/ml), and Tg Ab > 115 IU/ml, ranging from 280 to 3500 IU/ml (mean 
value  751  IU/ml).  The  28  patients  whose  FNAB  material  was  considered  as  control 
showed TPO Ab < 35 IU/ml, ranging from 7 to 11 IU/ml (mean value = 9 IU/ml), and Tg 
Ab < 115 IU/ml, ranging from 10 to 16 IU/ml (mean value 12 IU/ml).
All FNAB samples were immediately suspended in a small volume of sterile PBS (300 l), 
divided in two aliquots, frozen in liquid nitrogen, and conserved at -80°C until use. In two 
HT cases,  separated  epithelial  and lymphoid  FNAB fractions  were  obtained,  by using 
Dynal Epithelial Enrich method (Dynal AS, Oslo, Norway), based on immunomagnetic 
selection  of  cells  binding  to  EpCAM  (Ber-EP4)  antibodies.  The  obtained  fractions 
(epithelial-enriched  and  epithelial-depleted)  were  then  frozen  in  liquid  nitrogen,  and 
conserved at -80°C until use.
Peripheral  blood  from  patients  and  controls  was  also  collected.  Peripheral  blood 
mononuclear  cells  (PBMCs)  were  isolated  from  the  whole  heparinized  blood  by 
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Lympholyte-H   (CEDARLANE)  density  centrifugation.  Aliquots  of   106 PBMCs  were 
frozen in liquid nitrogen and maintained at -80°C for  DNA and RNA analyses and plasma 
fractions were also collected and frozen at -80°C until used.
2. Cell lines
Lymphoid CD4+ J-Jhan and SupT1 cell lines were used, respectively, for production of 
purified cell free virus inocula of HHV6 variants A (strain U1102) and B (strain CV). For 
in vitro infection experiments, we used Nthy-ori3-1 cell line, a thyroid follicular epithelial 
cell line 35. All cell lines were maintained in RPMI medium (Gibco) supplemented with 10 
% inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL of penicillin, and 
100 g/mL of streptomycin (Invitrogen, Carlsbad, CA).
3. Virus production and cells infection
Cell-free HHV6A inoculum (strain U1102) was obtained from infected J-Jhan cells, while 
cell-free HHV6B inoculum (strain CV) was obtained from SupT1 infected cells. Briefly, 
infected cells were collected by centrifugation and lysed by rapid freezing and thawing 
followed by sonication (3 cycles of 5 seconds at medium power with 10-second intervals in 
a water bath sonicator).  Cleared cellular content was added to culture supernatant,  and 
virions were collected by centrifugation for 30 minutes at 20000 x g at 4°C.
Virus particles were purified by density centrifugation on Optiprep self-forming gradients 
(Sentinel), at 58000 x g for 3.5 hours at 4°C. Purified virions were washed in phosphate 
buffered saline (PBS) and collected by centrifugation at 20000 x g for 30 minutes at 4°C.
Virions were suspended in sterile PBS containing 0.1% bovine serum albumin (BSA) and 
stored at -80°C until use.
Prior to use, virus stock was treated with DNase-I and RNase-A, to eliminate free viral 
nucleic acids eventually present in the preparation.
Infectivity  of  virus  preparation  was  evaluated  by  specifically  designed  infection 
experiments performed respectively in J-Jhan or SupT1 cells for variant A or B using PCR, 
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PCR after retrotranscription (RT-PCR) and immunofluorescence assays to evaluate virus 
presence, transcription, and antigen expression.
Quantification of virus genomes present in the stock preparation was obtained by real-time 
quantitative  PCR  (qPCR)144,  showing  that  inocula  contained  about  1010 genome 
equivalents per ml. Aliquots from the same stock were used for all infection experiments. 
Mock virus (used as negative control) was inactivated by UV irradiation as described 37.
Thyroid Nthy-ori3-1 cells were seeded at optimal density 24 hours before infection, then 
infected  with  a  m.o.i.  of  10:1  (10  genome  equivalents  per  1  cell).  After  3  hours  of 
adsorption followed by extensive washes, cells were incubated in complete medium and 
collected at specific time points for further analyses.
4. DNA extraction
Total DNA were isolated from FNABs, PBMCs and cultured Nthy-ori3-1 cells using 1 ml 
of lysis buffer (10 mM Tris-HCl pH 8.0, 10 mM disodium EDTA pH 8.0, 10 mM NaCl, 
0.6% SDS and 100 µg/ml proteinase K) and incubated at 37°C for a minimum time of 4 
hours.  After  three cycles  of  phenol:chloroform:isoamyl  alcohol  (25:24:1)  extractions  in 
Phase Lock Gel (PLG), DNA was precipitate in ethanol 100% and NaAc (CH3COONa pH 
5.0 300 mM) and stored at -80°C for at least 1h. After precipitation with ethanol, DNA 
pellets were dissolved in sterile water and stored at -20°C until PCR or qPCR analysis.  
DNA concentration was determined by reading optical density at 260 nm.
5. RNA extraction and retrotranscription
Total RNA was extracted with RNAzol B (Tel-Test), following manufacturer’s instructions. 
Briefly, samples were lysed with RNAzol, then chloroform in ratio 1:5 (v/v) was added. 
The mixture was centrifuged 20 minutes at 8500 x g,  the aqueous phase was collected and 
RNA precipitated with isopropanol 100%. After two washes with 75% ethanol and DNAse 
treatment (4 U/mg RNA, 3 x 20 minutes at room temperature), RNA was precipitated with 
isopropanol 20 minutes at 8500 x g at 4°C. RNA quality was checked by electrophoretic 
analysis on a 1% agarose gel. The absence of contaminating DNA was checked by PCR 
amplification of human β-actin gene before retrotranscription (RT-). Negative PCR results 
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for β-actin ensured that the RNA sample was completely free from DNA sequences. First 
strand  cDNA synthesis  was  carried  out  with  MuLV reverse  transcriptase  and  random 
hexamer  primers  (Applied  Biosystems),  following  the  manufacturer’s  instructions, 
retrotranscribing 2 µg of total RNA from all the samples. The mixture was incubated for 1 
hour  at  42°C.  Efficiency of  retrotranscription was assessed by analysis  of  dilutions  of 
cDNA with PCR specific for human β-actin gene (RT+).
6. PCR analyses
The  presence  and   transcription  of  HHV6  were  analyzed  by  PCR  and  PCR  after 
retrotranscription (RT-PCR) amplification of the U94 and U42 genes.
PCR and RT-PCR amplifications were respectively performed using 100 ng of total DNA 
or an amount of cDNA corresponding to 200 ng of total RNA extracted from samples. 
Amplification of the housekeeping β-actin gene was used as a control. Specific primers 
and PCR conditions are described in Table 2 and 3.
Table 2. Primer sets used for PCR and RT-PCR amplification.
As  already  described,  prior  to  retrotranscription  and  specific  PCR  amplification,  the 
absence of contaminating DNA was checked by PCR amplification of human β-actin gene 
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(RT-). Particular care was also taken to avoid sample-to-sample contamination: different 
rooms and dedicated equipment were used for DNA extraction and processing, for PCR 
set-up and gel analyses, all pipette tips had filters for aerosol protection.
Table 3.  Thermal conditions used for PCR and RT-PCR amplifications.
To quantify the amount of viral genomes or transcripts, we used a real time quantitative 
PCR (qPCR)  or  a  qPCR after  retrotranscription  (RT-qPCR),  analyzing  U94  and U42 
genes. RNase P housekeeping gene was used as internal control in order to normalize the 
results. qPCR reactions were performed using the 7300 ABI Prism (Applied Biosystems).
The DNA or cDNA copy numbers were quantified by comparison with standard curves 
obtained by using  a  10-fold  serial  dilutions  of  known concentrations  of  the  pSR2pH 
plasmid (containing the full length U94 gene)50 or of the amplification product of U42 
gene first round amplification (amplicon = 525bp).
Amplifications were carried out in a 50 µL total volume containing 25 µL 2X TaqMan 
Universal PCR Master Mix (Applied Biosystems), 5 µL of primer and probes, and 20 µL 
template. The target genes were amplified using TaqMan FAM-labelled probe at the 5’-
end and TAMRA quencher at the 3’-end. Primers and probes used are shown in Table 4. 
Primers and probes concentrations were respectively 900 nM for each primer and 200 nM 
for each probe.
The reaction conditions for all templates were 10 minutes at 95°C for enzyme activation, 
and 40 cycles with 15 seconds at 95°C for DNA denaturation and 1 minute at 60°C for 
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annealing and extension. Fluorescence data were collected in the primer elongation phase 
at 60°C. To normalise the data, the cycle threshold (Ct) values of the housekeeping gene 
were subtracted from the target gene Ct value of the sample.
Table 4. Primer and probe sets used for real time PCR quantifications.
7. Immunofluorescence assay (IFA)
Antigen expression of HHV6 in infected Nthy-ori3-1 cells was monitored by IFA, using a 
mouse mAb directed against gp116 of HHV6 (ABI, Columbia, MD). Cells infected with 
HHV6A or 6B were fixed in cold methanol:acetone 1:1 (30 min at -20°C), rehydrated in 
PBS and incubated for 35 minutes with the anti-gp116 mAb diluted 1:100 in PBS at 37°C 
in a humid chamber. Slides were then washed twice in PBS, once with tap water and once 
with  deionized  water,  then  incubated  with  a  secondary  goat  anti-mouse  IgG  antibody 
diluted 1:100 in PBS (AlexaFluor, Invitrogen) for 35 minutes at 37°C in a humid chamber. 
After four additional washes as described, slides were mounted with the mounting medium 
Vectashield  additioned  with  DAPI  staining  (Vector  Laboratories,  Burlingame,  CA)  for 
microscope observation. All samples were observed under a UV light microscope (Nikon 
Eclipse TE2000S) equipped with a digital camera.
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8. HLA class I and class II analyses
Surface expression of HLA class I and II (type DR) antigens was analyzed on Nthy-ori3-1 
cells  infected  with  HHV6 or  treated  with  recombinant  U94 virus  protein, prepared  as 
described  10. Thyroid cells were seeded at optimal density and infected with HHV6A or 
HHV6B as described above, or treated by adding 2 μg/ml of U94 protein to the culture 
medium. HHV7 infected cells  (at  the same m.o.i.)  and IFN-gamma (10 U/ml) (Roche, 
Mannheim, DE) treated cells were also used as internal controls, whereas uninfected cells 
were used as a negative control. The expression of surface HLA I or II (DR) antigens was 
analysed at 24, 48 and 72 hours post infection/treatment, by a cytofluorimetric approach 
with FACS Count flow cytometer (Becton Dickinson, San Jose, CA, USA) using standard 
settings and Cell Quest software (Becton Dickinson, San Jose, CA, USA) for data analysis. 
Briefly, cells were collected, washed in PBS and stained with anti-HLA I (W6/32, IgG2a, 
FITC) and anti-HLA DR mAb (L243, IgG2a, PECy5.5) (Caltag Laboratories, CA, USA). 
Anti-isotype controls (Exbio, Praha, Czech Republic) have been performed.
9. Killing assay
In vitro killing experiments were performed using Nthy-ori3-1 cells as the target cells and 
PBMC from healthy donors  as  the  effector  cells.  Thyroid  cells  were  seeded at  optimal 
density in 6 wells (5x105 cells/well), and infected with HHV6 as described (m.o.i. 10:1). 
Following 3 hours of adsorption, cells were washed and incubated in complete medium for 
24,  48 and 72 hours.  PBMCs were then  added to infected or  uninfected  cells,  used as 
negative control, using an effector: target (E:T) ratio of 2:1. K562 cells were also used as 
target cells for a positive control of NK activation. NK killing ability was evaluated after 4 
hours, a time chosen to evidence NK innate activity 39-40, by Annexin-V quantification and 
CD107a exposure. Each sample was performed in triplicate.
For Annexin-V analysis, adherent thyroid cells were collected separately from suspension 
cells (PBMC), stained with FITC-labelled Annexin-V (Bender MedSystem, Vienna, AU) 
and analysed by cytofluorimeter. Propidium Iodide staining was also used to assess cell 
viability, detecting late apoptosis.
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  Material & Methods  
       
For  quantification  of  degranulation,  non-adherent  cells  were  stained  with  PE-Cy5 
conjugated anti-CD107a mAb (e-Bioscience, Frankfurt, DE). After 1 hour of incubation at 
37°C and 3 hours of treatment with Golgi Stop solution (Becton Dickinson, San Jose, CA, 
USA),  cells  were  stained  with  anti-CD3-PerCp-Cy5.5  and  anti-CD56-FITC  mAbs  (e-
Bioscience, Frankfurt, DE), and analyzed by flow cytometric analysis, acquiring 10,000 
events. NK cells were defined as CD3-/CD56+ cells within the lymphocyte gate.
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DISCUSSION
Viral  infections  have  been  frequently  considered  as  critical  environmental  factors 
implicated  in  HT pathogenesis  147,141,  but  no  specific  virus  has  yet  been  conclusively 
associated with the disease. In particular, herpesviruses have been also implicated, with 
contrasting evidence. Case reports suggested a potential association between herpesvirus 
infection  and HT,  142,  148,  149,150 but  when thyroid FNAB specimens were  analysed,  no 
herpesvirus DNA was detected  157. A recent study analysed the presence of herpesvirus 
DNA in post-operative thyroid specimens from tissue blocks 142, and HHV6 was detected 
by single round PCR in 2 out of 15 (13.3%) HT tissue specimens, whereas no HHV6 DNA 
was isolated in Grave’s Disease or Multi Nodular Goiter tissues.
In the present work, employing a sensitive real time qPCR, 28/34 samples were positive to 
HHV6 DNA. To ensure that positivity was specific, we amplified two different regions of 
HHV6 DNA (U42 and U94), obtaining similar viral loads for both genes. In particular, the 
majority of HT specimens harboured high viral (> 103 copies/μg of human DNA), whereas 
control  thyroid  tissues  were  consistently  negative.  Statistical  analysis  showed  that 
differences  in  HHV6  prevalence  were  highly  significant,  considering  HT  vs controls 
(p<0.001). The possibility that positive HHV6 results in HT FNABs reflects contamination 
of  blood harbouring latent  HHV6 was ruled  out  by the  observation  that  viral  DNA is 
preferentially present in the epithelial fraction and not in lymphoid cells.
The analysis of peripheral blood samples showed that HHV6 was present exclusively in a 
latent  state  both in  HT patients  and in  controls  (patients  with multinodular  goiter  and 
healthy  donors), but  viral  loads  were  markedly  higher  in  HT patients  (about  5.5x103 
copies/μg cell DNA), compared to MNG (4.5x102 copies/μg DNA) and healthy subjects 
(5x102 copies/μg DNA).
We also provide evidence indicating that HHV6 infects follicular thyroid cells, with the 
typical  behaviour  of  herpesviruses,  i.e.  onset  of  productive  infection  followed  by 
persistence in a latent form. In fact, productive infection was detected up to 7 days p.i., as 
shown both by transcription analysis and IFA staining. Subsequently, latent infection was 
established, as shown by persistence of viral DNA in the presence of the latency-associated 
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U94 gene. Therefore, HHV6 is capable of long-term persistence in follicular cell elements 
of the thyroid.
HHV6 in vitro infection of Nthy-ori3-1 cells results in the induction of  HLA class II (DR) 
expression on thyroid follicular cells, which may thus behave as antigen presenting cells 
promoting the autoimmune responses underlying HT development. This observation was 
already reported  for  human cytomegalovirus  infection  both  in  primary endothelial  and 
thyroid cells  145,151,  suggesting that  infection by  β-herpesviruses could be associated to 
immune dysfunction, such as autoimmune disorders. Furthermore, HHV6 infected thyroid 
cells become targets for the cytotoxic activity mediated by innate immunity effectors, as 
shown  by  killing  experiments  performed  after  4  hours  of  incubation  with  PBMCs, 
suggesting that virus infection might trigger the activation of immune cells which could 
attack and destroy infected thyroid cells.
The detection of viral footprints in pathologic specimens does not necessarily prove that 
the pathogen is responsible for the disease, especially in the case of a ubiquitous agent such 
as  HHV6.  Nevertheless,  the  results on  the  high  prevalence  of  HHV6 infection  in  HT 
samples  and  the  fact  that  follicular thyroid  cells  support  both  lytic  and  latent  HHV6 
infection show for the first time that HHV6 is strictly associated with HT, and should be 
considered an important environmental factor implicated in the pathogenesis of disease. 
Further studies are however required to elucidate the mechanisms underlying the possible 
role of HHV6 as a trigger of HT. Indeed, there are several potential mechanisms by which 
HHV6 might induce autoimmune responses. On a theoretical level, viral infections might 
trigger autoimmunity by suddenly exposing high amounts of normally sequestered cell 
antigens,  through  lysis  of  infected  cells.  Another  potential  trigger  is  represented  by 
molecular mimicry, with the synthesis of viral proteins that resemble cellular molecules, as 
a mechanism of immune escape. Viral infection often induces the synthesis of cytokines 
and chemokines, that might have undesired effects on physiologic immune mechanisms. 
Finally, the virus could induce aberrant expression of histocompatibility molecules thereby 
promoting the presentation of auto-antigens.
Notably, HHV6 has the ability to induce all the above mentioned mechanisms and in the 
recent years, several anecdotic reports have repeatedly suggested a potential role of HHV6 
in autoimmunity 152,153,154,155,156. Even if this results do not prove a causal association, they 
provide a proof of concept for further studies aimed to analyse HHV6 persistence in the 
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thyroid,  to  elucidate  local  interactions  with  the  immune  system,  and  to  identify 
predisposing genetic factors.
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